Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8
Interventions: DRUG: Abemaciclib|DRUG: Anastrozole|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Palbociclib|DRUG: Ribociclib
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)